Study S000547

A Pilot Prospective Comparison of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05034783
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Masking: NONE
Status: UNKNOWN
Enrollment: 20
Start: 2021-10-01
Primary completion: 2022-10-13
Lead sponsor: Peking Union Medical College Hospital
Conditions: Insulinoma
Interventions: DRUG:[68Ga]Ga-HBED-CC-exendin-4; DRUG:[68Ga]Ga-NOTA-exendin-4
Results posted: FALSE

Registered primary outcomes

Metabolic parameters [through study completion, an average of 1 year]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009503	Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4. Li L, Clinical nuclear medicine	2025	Other	PMID 39499011 DOI	cites ClinicalTrials.gov:NCT05034783; registry reference DERIVED:39499011